Literature DB >> 11686341

Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint.

B R Saxon, D Shanks, C B Jory, V Williams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11686341

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  10 in total

1.  The expanding role of prophylaxis with recombinant activated factor VII.

Authors:  Annarita Tagliaferri; Massimo Franchini
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

2.  Increased Accumulation and Retention of rhFVIIa (eptacog beta) in Knee Joints of Hemophilia A Mice Compared to Wild-Type Mice.

Authors:  Jhansi Magisetty; Usha R Pendurthi; SubbaRao V Madhunapantula; Jerry Grandoni; L Vijaya Mohan Rao
Journal:  Thromb Haemost       Date:  2019-05-26       Impact factor: 5.249

3.  Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy.

Authors:  D M Cohn; M Goddijn; S Middeldorp; J C Korevaar; F Dawood; R G Farquharson
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

4.  rFVIIa transported from the blood stream into tissues is functionally active.

Authors:  R Gopalakrishnan; U Hedner; C Clark; U R Pendurthi; L V M Rao
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

5.  Animal models of FVIIa gene expression: their role in the future development of haemophilia treatment.

Authors:  A Obergfell; T Nichols; M Ezban
Journal:  Haemophilia       Date:  2010-03       Impact factor: 4.287

6.  Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa).

Authors:  R Gopalakrishnan; U Hedner; S Ghosh; R C Nayak; T C Allen; U R Pendurthi; L V M Rao
Journal:  J Thromb Haemost       Date:  2009-11-23       Impact factor: 5.824

7.  Postoperative pulmonary thromboembolism possibly associated with recombinant activated factor VII infusion for the treatment of uncontrolled hemorrhage during vertebral instrumentation.

Authors:  Zahid Hussain Khan; Alireza Ebrahim Soltani; Payman Rahmani
Journal:  J Anesth       Date:  2007-05-30       Impact factor: 2.078

8.  Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors.

Authors:  Ampaiwan Chuansumrit; Pantep Angchaisuksiri; Nongnuch Sirachainan
Journal:  J Blood Med       Date:  2010-03-30

9.  Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa.

Authors:  C A Clark; R Vatsyayan; U Hedner; C T Esmon; U R Pendurthi; L V M Rao
Journal:  J Thromb Haemost       Date:  2012-11       Impact factor: 5.824

Review 10.  Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.

Authors:  Geir E Tjønnfjord; Pål Andre Holme
Journal:  Vasc Health Risk Manag       Date:  2007
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.